RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories (BIO) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $300 to $430.
Express News | Bio Rad Laboratories Inc : RBC Cuts Target Price to $402 From $414
Bio-Rad Laboratories on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Bio-Rad Laboratories, Inc. Class A (BIO) is currently at $298.34, up $16.08 or 5.7% --Would be highest close since May 15, 2024, when it closed at $300.97 --On pace for largest percent increase sinc
$842.7 Million SDS Poly Acrylamide Gel Electrophoresis Market Forecast, 2030 - Featuring Profiles of 13 Companies Including Abcam, Bio-Rad Laboratories, GE Healthcare, and Thermo Fisher Scientific
There's Reason For Concern Over Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Price
With a median price-to-sales (or "P/S") ratio of close to 3.1x in the Life Sciences industry in the United States, you could be forgiven for feeling indifferent about Bio-Rad Laboratories, Inc.'s (NY
Bio-Rad Laboratories(BIO.US) Officer Sells US$104.02K in Common Stock
$Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael sold 369 shares of common stock on Jun 13, 2024 at an average price of $281.9064 for a total value of $104.02K.Source: Announcement What is state
Is Bio-Rad Laboratories (BIO) a Lucrative Investment?
Form 144 | Bio-Rad Laboratories(BIO.US) Officer Proposes to Sell 104.02K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael intends to sell 369 shares of its common stock on Jun 13, with a total market value of approximately $104.02K.
Citi Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Cuts Target Price to $300
Citi analyst Patrick B Donnelly maintains $Bio-Rad Laboratories(BIO.US)$ with a hold rating, and adjusts the target price from $365 to $300.According to TipRanks data, the analyst has a success rate o
Bio-Rad Laboratories Coverage Assumed by Jefferies at Hold Vs Previous Rating of Buy
Bio-Rad Laboratories Coverage Assumed by Jefferies at Hold Vs Previous Rating of Buy
Express News | Jefferies Financial Investment Bank adjusted the rating of Bio-Rad Laboratories (BIO.US) from buy to hold, with a target price of $315.00, down from $440.00.
Jefferies Assumes Bio-Rad Laboratories at Hold, Lowers Price Target of $315
Jefferies assumes Bio-Rad Laboratories (NYSE:BIO) with a Hold rating and lowers Price Target of $315.
Express News | Bio Rad Laboratories Inc : Jefferies Assumes Coverage With Hold Vs Buy Rating; Price Target $315 Vs $440
Express News | Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K.
Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target
Last week saw the newest quarterly earnings release from Bio-Rad Laboratories, Inc. (NYSE:BIO), an important milestone in the company's journey to build a stronger business. The analysts typi
Bio-Rad Laboratories | 10-Q: Quarterly report
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories (BIO) has an average outperform rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 271.46, Change: -8.45, Percent Change: -3.02
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS